tickdelta
Sign in
Screener / SEC EDGAR /CIK 0000310764 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Medical Instruments

Stryker Corporation SYK

SYK quote by TradingView
Employees
56,000
Headquarters
Portage, MI
Next results
around Jan 28, 2027
Compare with peers Embed

Where each dollar of revenue went, FY2025

Revenue of $25.1B through the costs to a net profit of $3.2B · income statement of the 10-K

19% operating margin
Revenue to Gross profit: $16.1BRevenue to Cost of revenue: $9.1BGross profit to Operating profit: $4.9BGross profit to Operating expenses: $11.2BOperating profit to Net profit: $3.2BOperating profit to Tax & other: $1.6BOperating expenses to R&D: $1.6BOperating expenses to Sales, admin & other: $9.6B Revenue: $25.1B REVENUE $25.1B +11% Y/Y Gross profit: $16.1B · 64% margin GROSS PROFIT $16.1B 64% margin · +11% Y/Y Cost of revenue: $9.1B · 36% of revenue COST OF REVENUE $9.1B 36% of revenue Operating profit: $4.9B · 19% margin OPERATING PROFIT $4.9B 19% margin · +33% Y/Y Operating expenses: $11.2B · 44% of revenue OPERATING EXPENSES $11.2B 44% of revenue Net profit: $3.2B · 13% margin NET PROFIT $3.2B 13% margin · +8% Y/Y Tax & other: $1.6B · 7% of revenue TAX & OTHER $1.6B 7% of revenue R&D: $1.6B · 6% of revenue R&D $1.6B 6% of revenue Sales, admin & other: $9.6B · 38% of revenue SALES, ADMIN & OTHER $9.6B 38% of revenue
Gross profit $16.1B 64% margin · +11% Y/Y
Operating profit $4.9B 19% margin · +33% Y/Y
Net profit $3.2B 13% margin · +8% Y/Y
The full income statement, year by year

SYK among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 59 peers the company is above, not a score.

Compare
Revenue growth: 11.2%, above 75% of 59 peers (their median 7.1%) REVENUE GROWTH 11.2% · above 75% Gross margin: 65.3%, above 52% of 50 peers (their median 64.2%) GROSS MARGIN 65.3% · above 52% Operating margin: 20.7%, above 74% of 50 peers (their median 13.4%) OPERATING MARGIN 20.7% · above 74% Net margin: 13.8%, above 61% of 59 peers (their median 9.5%) NET MARGIN 13.8% · above 61% FCF margin: 17.4%, above 60% of 55 peers (their median 15.2%) FCF MARGIN 17.4% · above 60% Return on capital: 9.3%, above 56% of 41 peers (their median 9.0%) RETURN ON CAPITAL 9.3% · above 56%
SYK Peer median Below the median

What changed

1 accounting fact worth reading about.

Risk factors
No new paragraphs, or fewer than two 10-Ks to compare
10-K Item 1A
Critical audit matters changed
New this year: Description As described in Note 11 to the consolidated financial statements, the Company is involved in various income tax matters; Auditing management’s evaluation of the uncertain tax positions associated with the FCTO tax assessments was; How We We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the; Addressed Company’s accounting process for uncertain tax positions. For example, we tested controls over management’s; Our audit procedures included, among others, evaluating the assumptions the Company used to assess its uncertain tax; Acquisitions; Description As described in Note 6 to the consolidated financial statements, in 2025 the Company completed the acquisition of Inari; How We We obtained an understanding, evaluated the design and tested the operating effectiveness of the controls over the; Addressed identification and measurement of developed technologies. For example, we tested controls over the valuation of; Our Audit To test the fair value measurement of developed technologies, we performed audit procedures that included, among. Same as last year: Uncertain Tax Positions
10-K · XBRL
Accounting checks
10 other checks clear, 1 worth a look
10-K · XBRL
Insiders
No open-market buys in the last 90 days
Form 4
Filings
5 in the last 30 days
EDGAR

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

11 checks on the latest 10-K. Checks, not verdicts.

How it works

1fact worth reading about the other 10 checks found nothing to note

  • Critical audit matters changed
    New this year: Description As described in Note 11 to the consolidated financial statements, the Company is involved in various income tax matters; Auditing management’s evaluation of the uncertain tax positions associated with the FCTO tax assessments was; How We We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the; Addressed Company’s accounting process for uncertain tax positions. For example, we tested controls over management’s; Our audit procedures included, among others, evaluating the assumptions the Company used to assess its uncertain tax; Acquisitions; Description As described in Note 6 to the consolidated financial statements, in 2025 the Company completed the acquisition of Inari; How We We obtained an understanding, evaluated the design and tested the operating effectiveness of the controls over the; Addressed identification and measurement of developed technologies. For example, we tested controls over the valuation of; Our Audit To test the fair value measurement of developed technologies, we performed audit procedures that included, among. Same as last year: Uncertain Tax Positions
  • Receivables +1.3% vs revenue +11.2% (-9.9 pts)
9 more checks with nothing to note
  • Cash from operations $5.0B vs net income $3.2B (FY ending Dec 31, 2025)
  • Inventory +11.2% vs revenue +11.2% (+0.1 pts)
  • Same auditor in both 10-Ks: Ernst & Young LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

No new paragraphs in Risk Factors

No new paragraphs in Risk Factors, or fewer than two 10-Ks to compare.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$18.4B$20.5B$22.6B$25.1B
Net income$2.4B$3.2B$3.0B$3.2B
Operating cash flow$2.6B$3.7B$4.2B$5.0B
Free cash flow$2.0B$3.1B$3.5B$4.3B

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$25.1B ▲ 11.2% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

5 filings in the last 30 days · SEC EDGAR

All filings

About the company

Stryker Corporation, Portage, MI · from the 10-K filed Feb 11, 2026

Net Sales by Reportable Segment 2025 2024 2023 MedSurg and $15,647 62% $13,518 60% $12,163 59% Neurotechnology Orthopaedics 9,469 38 9,077 40 8,335 41 Total $25,116 100% $22,595 100% $20,498 100% Composition of MedSurg and Neurotechnology Net Sales 2025 2024 2023 Instruments $3,183 20% $2,834 21% $2,534 21% Endoscopy 3,807 24 3,389 25 3,068 25 Medical 4,204 27 3,852 28 3,459 28 Vascular 1,968 13 1,307 10 1,226 11 Neuro Cranial 2,485 16 2,136 16 1,876 15 Total $15,647 100% $13,518 100% $12,163 100%

Headquarters
Portage, MI
Country
United States
Reports in
USD
Listed on
NYSE
Fiscal year ends
December 31
Last results
Oct 29, 2026
Incorporated in
MI

Employees, at the top of the page: "On December 31, 2025 we had approximately 56,000 employees globally, with approximately 28,000 employees in the United States" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/SYK/export.csv") into a cell.